Latest stories on STOK
Stoke Therapeutics: Its Dravet Syndrome Lead Asset Enters The Last Stretch
Seeking Alpha67 · bullishproduct/pr
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | STOK Stock News
StockTitan50 · neutralgeneral
Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer | BIIB Stock News
StockTitan56 · neutralproduct/pr
Stoke Therapeutics Completes Enrollment in Phase 3 Dravet Trial
TipRanks63 · neutralproduct/pr
Stoke Therapeutics, Inc. (STOK) files 8-K
SEC 8-K50 · neutralgeneral
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | STOK Stock News
StockTitan50 · neutralgeneral
Stoke Therapeutics, Inc. (STOK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha55 · neutralgeneral
Stoke Therapeutics Stockholders Approve Directors and Governance Items
TipRanks50 · neutralgeneral
Stoke Therapeutics, Inc. (STOK) Reports Q1 Results and Business Updates
Yahoo Top56 · neutralearnings
Stoke Therapeutics to Present at Upcoming Investor Conferences in June | BIIB Stock News
StockTitan56 · neutralproduct/pr
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Morningstar50 · neutralgeneral